On February 6, 2023 LIDDS AB (publ) ("LIDDS"or the "Company") reported the preliminary outcome of the righs issue with preferential rights for the shareholders (the "Rights Issue"), which subscription period ended today (Press release, Lidds, FEB 6, 2023, View Source [SID1234626890]). The subscription breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights Issue, were subscribed for with or without the exercise of subscription rights. The Rights Issue was secured to approximately 95.7 percent through issue gurantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I would like to thank all existing shareholders who have participated in the rights issue for your continued support and extend a warm welcome to new shareholders. The rights issue provides a significant reinforcement to the Company’s continued development of Nanodotax and Nanoimod and enables intensified work with the out-licensing of the Phase III project Liproca Depot", says Anders Månsson, CEO of LIDDS.

The subscription period in the Rights Issue ended today the 6 February 2023 and a preliminary breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights issue, were subscribed for with or without the exercise of subscription rights. No investors who have issued guarantees will preliminary be allocated any shares. The Rights Issue was secured to approximately 95.7 percent through issue guarantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.

The final outcome of the Rights Issue is expected to be announced on Wednesday 8 February 2023. Allocation of shares that were subscribed for without the exercise of subscription rights will be done according to the principles described in the prospectus that was prepared in connection with the Rights Issue and was published on 17 January 2023. Those who will be allocated shares without the support of subscription rights will be notified after the allocation meeting held by the Board of Directors on 8 February 2023 through contract note. Nominee shareholders will receive notification of allotment in accordance with the respective nominee’s routines. Allocated shares should be paid according to the instructions on the contract note.

Advisors
Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.